Author:
Mauer Karin,Saucedo Jorge F.
Abstract
AbstractAspirin, ticlopidine, clopidogrel, and IIb/IIIa inhibitors have been widely used in acute coronary syndromes (ACS) and following bare metal and drug‐eluting stent placement. Clopidogrel is superior to aspirin in reducing ischemic vascular events in high‐risk patients and has improved gastrointestinal tolerance but is associated with rash, diarrhea, and adverse hematologic outcomes. Combination antiplatelet therapy with aspirin and a thienopyridine is the optimal currently available combination following percutaneous coronary intervention (PCI) and in patients with an ACS. As this chapter will discuss, current advances in the development of new antiplatelet agents will provide a wider selection of therapeutic options for the management of cardiovascular patients.
Reference183 articles.
1. Clopidogrel Response Variability, Resistance, or Both?
2. Clinical applications of antiplatelet therapy;Wiviott SD;Rev Cardiovasc Med,2006
3. Platelet activation and progression to complications;Kereiakes DJ;Rev Cardiovasc Med,2006
4. Antiplatelet drugs;Born G;Br J Pharmacol,2006
5. Platelet Hyperreactivity: Predictive and Intrinsic Properties